ARCH Venture Partners
-
Paradigm Launches with $203M to Transform Clinical Trial Recruitment
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
-
Autoimmune Drug Biotech HI-Bio Unveils $120M to Root Out Cellular Drivers of Disease
Human Immunology Biosciences aims to stand apart in autoimmune disease drug research with therapies that address cells at the root of a range of allergic and inflammatory disorders. The biotech has a lead program licensed from MorphoSys in clinical development for two rare kidney diseases and $120 million to support that antibody and other biologic drugs in its pipeline.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Mental health startup for seniors rakes in $32M from General Catalyst, Mass General Brigham Ventures, others
There is a dearth of professionals with licenses and training to provide care for seniors’ mental and behavioral health challenges — such as Alzheimer’s and other dementias, anxiety and depression. Seattle-based Rippl Care is seeking to change this. The startup just closed a $32 million seed funding round led by ARCH Venture Partners and General Catalyst.
-
Cell therapy developer Be Bio hauls in $130M for pipeline in rare disease, cancer
Be Biopharma is developing cell therapies by engineering B cells to churn out therapeutic proteins with an initial focus on cancer and rare disease. The company’s Series B financing comes as competitors in the space also make progress with their engineered B cell therapies.
-
RNA biotech Nutcracker Therapeutics unshells $167M for drugs built on biochips
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and manufacturing RNA therapies borrows from techniques used in the technology sector.
-
Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs
Neumora Therapeutics unveiled $500 million in capital and a research partnership with Amgen. The startup analyzes neurological data to inform its drug research and development; President and Chief Operating Officer Lori Lyons-Williams said researching psychiatric drugs and neurodegenerative drugs within the same company allows brain insights from one area to inform the other.
-
Backed by $92M, startup Interline aims to shed new light on protein communities
Interline Therapeutics has technology that shows how proteins interact as communities, paving the way for the discovery of new drugs. CEO Zachary Sweeney, a Denali Therapeutics veteran, said the startup will use the $92 million in funding to advance programs in cancer and inflammatory diseases.
-
Here’s how Covid-19 has affected funding, development in infectious diseases
“Everybody’s an infectious disease company now,” ARCH Venture Partners Managing Director Bob Nelsen said. By contrast, a report last year showed a huge decline in venture capital investment in the infectious disease space.
-
Glympse Bio raises more than $46M in Series B round for biosensor technology
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics – one of the earliest commercial developers of CAR-T cell therapy technology – in 2013.
-
ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B
On Thursday, Flagship announced it had closed a fund worth $1.1 billion, while ARCH closed two funds worth a combined $1.46 billion. Both firms’ announcements included nods to the ongoing Covid-19 pandemic.
-
With $200M Series A, EQRx aims to tackle high drug prices
The startup, founded by a prominent health policy expert and a biotech industry executive, aims to bring down the cost of drugs by re-engineering and making less costly the process by which they are discovered and brought to patients.
-
Verve Therapeutics aims to tackle heart disease through gene editing
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
-
What’s behind sky-high valuations of biopharma startups?
It was a banner year for biopharma, with records broken in deal values, number of exited unicorns and the biggest-ever biotech IPO. But where do these unicorn valuations come from?
-
Single-letter gene editing startup Beam Therapeutics raises $135M Series B round
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
